3D LifePrints UK Ltd, one of the UK’s leading medical 3D printing companies, has closed a Series A investment round of £500,000 with Fenwall Investments Ltd. This investment follows on from previous Seed Funding investment in 2016 and will enable accelerated expansion for this award-winning innovative company.
“We are extremely pleased to announce the completion of this funding round which will accelerate our unique model of embedded 3D medical printing services to drive down operational costs, provide innovative 3D technology based products and services, and ultimately improve patient care.” Paul Fotheringham, Founder and Chief Technology Officer for 3D LifePrints.
3D LifePrints provides medical 3D printing manufacturing and service capabilities for key NHS hospitals & academic institutions. They partner with clinicians, healthcare providers and academics to identify new applications of 3D technologies. 3D LifePrints already provide a variety of innovative 3D printed products to reduce operational costs and enhance patient care.
“I’m delighted that Fenwall have invested with us. They are a perfect long-term partner for 3D LifePrints, with a shared set of values and a vision for improving healthcare across the globe.” Henry Pinchbeck, CEO LifePrints
The investment will be used by 3D LifePrints to expand their portfolio of embedded medical 3D printing hubs across the NHS and overseas, recruit additional bio-medical engineers and 3D technologists, as well as continuing to invest in Research and Development.
“We’re delighted to be on board with this talented team operating in an emerging and fast-developing market. We feel the timing is perfect to allow 3D LifePrints to capitalise on its potential. I’m looking forward to an exciting and profitable partnership.” Dr. Andrew Douglas, Managing Director of Fenwall Investments Ltd.